Supriya Lifescience Leaders Shine in Hurun Women's List
This year's theme, 'Celebrating Women Creating Opportunities,' perfectly reflects the leadership philosophy of both honorees. Their inclusion highlights not only their contribution to the pharmaceutical industry but also their impact in creating inclusive, purpose-driven workplaces and innovations in sustainable healthcare.
Dr. Saloni Wagh, Managing Director, expressed that leadership in pharma must be anchored in innovation and responsibility.
'This recognition energizes our mission to create impactful, sustainable healthcare solutions,' she said.
Ms. Shivani Wagh, Joint Managing Director, dedicated the honour to women leaders and teams that support shared progress.
'Our success stems from collaboration and commitment. It's an honour to be part of a platform that values intent as much as impact,' she added.
The Candere Hurun List 2025 features women who have built over ₹2 lakh crore in self-made wealth and lead enterprises with a combined value exceeding ₹12 lakh crore. The recognition underscores excellence in entrepreneurship, leadership, and contribution to India's economic growth.
This milestone comes as Supriya Lifescience celebrates its highest-ever financial year, reporting ₹696.48 crore in FY25 revenue, a 22% YoY growth. Under their joint leadership, the company continues to scale new heights in global pharma while championing ethical growth, diversity, and innovation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
4 days ago
- Fashion Value Chain
Supriya Lifescience Q1 FY26 Revenue at Rs 145 Cr
Supriya Lifescience Ltd., a cGMP-compliant API manufacturer with a presence in over 86 countries, has announced its unaudited Q1 FY26 financial results. The company operates across multiple therapeutic categories, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic segments. Consolidated Financial Results (Q1 FY26 vs Q1 FY25): Revenue: Rs 145.07 crore, down 9.7% YoY (vs Rs 160.63 crore) EBITDA: Rs 51.7 crore (vs Rs 62.54 crore) EBITDA Margin: 35.6% (vs 38.9%) PAT: Rs 34.79 crore (vs Rs 44.64 crore) PAT Margin: 24.0% (vs 27.8%) Quarterly EPS: Rs 4.3 (vs Rs 5.5) Operational Highlights: Anaesthetic segment drove revenue, contributing 53% vs 45% in Q1 FY25. European markets' share rose to 41% from 34% last year. Capacity utilisation improved to 76% in FY26 from 70% in FY25. Acquired three land parcels near existing plants to support future growth. Management Comment: Mr. Satish Wagh, Chairman and Managing Director, stated, 'Our Q1 results reflect temporary impact from necessary repairs at the Lote facility to enhance efficiency and support new product launches. Despite revenue decline, margins stayed robust at 36% owing to backward integration and stronger regulated market contributions. With the Ambernath site nearing commercialisation in Q4, 3–4 new product launches in FY26, and sustained demand across key therapeutic areas, we anticipate recovery in H2 and remain confident of achieving ~20% growth and Rs 1,000 crore revenue by FY27.' Supriya Lifescience continues to strengthen its API portfolio with expansion plans, capacity enhancements, and a focus on regulated markets.
Business Standard
6 days ago
- Business Standard
Supriya Lifescience standalone net profit declines 22.07% in the June 2025 quarter
Sales decline 9.69% to Rs 145.07 crore Net profit of Supriya Lifescience declined 22.07% to Rs 34.79 crore in the quarter ended June 2025 as against Rs 44.64 crore during the previous quarter ended June 2024. Sales declined 9.69% to Rs 145.07 crore in the quarter ended June 2025 as against Rs 160.63 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 145.07160.63 -10 OPM % 35.6438.94 - PBDT 53.8764.43 -16 PBT 47.4259.77 -21 NP 34.7944.64 -22
Fashion Value Chain
06-06-2025
- Fashion Value Chain
Supriya Lifescience Leaders Shine in Hurun Women's List
A remarkable achievement for women-led enterprise, Dr. Saloni Wagh and Ms. Shivani Wagh of Supriya Lifescience Ltd. have been featured in the 2025 Candere Hurun India Women Leaders List, an annual showcase of India's most influential women in business and leadership. This year's theme, 'Celebrating Women Creating Opportunities,' perfectly reflects the leadership philosophy of both honorees. Their inclusion highlights not only their contribution to the pharmaceutical industry but also their impact in creating inclusive, purpose-driven workplaces and innovations in sustainable healthcare. Dr. Saloni Wagh, Managing Director, expressed that leadership in pharma must be anchored in innovation and responsibility. 'This recognition energizes our mission to create impactful, sustainable healthcare solutions,' she said. Ms. Shivani Wagh, Joint Managing Director, dedicated the honour to women leaders and teams that support shared progress. 'Our success stems from collaboration and commitment. It's an honour to be part of a platform that values intent as much as impact,' she added. The Candere Hurun List 2025 features women who have built over ₹2 lakh crore in self-made wealth and lead enterprises with a combined value exceeding ₹12 lakh crore. The recognition underscores excellence in entrepreneurship, leadership, and contribution to India's economic growth. This milestone comes as Supriya Lifescience celebrates its highest-ever financial year, reporting ₹696.48 crore in FY25 revenue, a 22% YoY growth. Under their joint leadership, the company continues to scale new heights in global pharma while championing ethical growth, diversity, and innovation.
